Reply to: Antidepressant Actions of Ketamine Versus Hydroxynorketamine

Biological Psychiatry

Volumn 81, Issue 8, 2017, Pages e69-e71

  Zanos, Panos ^a   Moaddel, Ruin ^a   Morris, Patrick J ^c   Wainer, Irving W ^e   Albuquerque, Edson X ^a,b   Thompson, Scott M ^a   Thomas, Craig J ^c   Zarate, Carlos A ^d   Gould, Todd D ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPA RECEPTOR; ANTIDEPRESSANT AGENT; DRUG METABOLITE; HYDROXYNORKETAMINE; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PLACEBO; UNCLASSIFIED DRUG;

ANTIDEPRESSANT ACTIVITY; CONTROLLED CLINICAL TRIAL (TOPIC); DEPRESSION; DRUG BRAIN LEVEL; DRUG METABOLISM; FORCED SWIM TEST; HUMAN; LEARNED HELPLESSNESS TEST; LETTER; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS (TOPIC); MONTGOMERY ASBERG DEPRESSION RATING SCALE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; SINGLE DRUG DOSE;

ANTIDEPRESSIVE AGENTS; HUMANS; KETAMINE;

EID: 85005790389     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2016.08.039     Document Type: Letter

References (23)

1. 1 Zanos, P., Moaddel, R., Morris, P.J., Georgiou, P., Fischell, J., Elmer, G.I., et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 533 (2016), 481–486.
2. 2 Zarate, C.A. Jr, Brutsche, N., Laje, G., Luckenbaugh, D.A., Venkata, S.L., Ramamoorthy, A., et al. Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression. Biol Psychiatry 72 (2012), 331–338.
3. 3 Collingridge, G., Lee, Y., Bortolotto, Z., Kang, H., Lodge, D., Antidepressant actions of ketamine versus hydroxynorketamine. Biol Psychiatry 81 (2017), e65–e67.
4. 4 Singh, J.B., Fedgchin, M., Daly, E., Xi, L., Melman, C., De Bruecker, G., et al. Intravenous esketamine in adult treatment-resistant depression: A double-blind, double-randomization, placebo-controlled study. Biol Psychiatry 80 (2016), 424–431.
5. 5 Zarate, C.A. Jr, Singh, J.B., Carlson, P.J., Brutsche, N.E., Ameli, R., Luckenbaugh, D.A., et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63 (2006), 856–864.
6. 6 Berman, R.M., Cappiello, A., Anand, A., Oren, D.A., Heninger, G.R., Charney, D.S., et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47 (2000), 351–354.
7. 7 Diazgranados, N., Ibrahim, L., Brutsche, N.E., Newberg, A., Kronstein, P., Khalife, S., et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 67 (2010), 793–802.
8. 8 Murrough, J.W., Iosifescu, D.V., Chang, L.C., Al Jurdi, R.K., Green, C.E., Perez, A.M., et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: A two-site randomized controlled trial. Am J Psychiatry 170 (2013), 1134–1142.
9. 9 Singh, J.B., Fedgchin, M., Daly, E.J., De Boer, P., Cooper, K., Lim, P., et al. A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry 173 (2016), 816–826.
10. 10 Murrough, J.W., Perez, A.M., Pillemer, S., Stern, J., Parides, M.K., aan het Rot, M., et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 74 (2013), 250–256.
11. 11 Zarate, C.A. Jr, Brutsche, N.E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., et al. Replication of ketamine's antidepressant efficacy in bipolar depression: A randomized controlled add-on trial. Biol Psychiatry 71 (2012), 939–946.
12. 12 Yang, C., Shirayama, Y., Zhang, J.C., Ren, Q., Yao, W., Ma, M., et al. R-ketamine: A rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry, 5, 2015, e632.
13. 13 Zhang, J.C., Li, S.X., Hashimoto, K., R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine. Pharmacol Biochem Behav 116 (2014), 137–141.
14. 14 Sanacora, G., Smith, M.A., Pathak, S., Su, H.L., Boeijinga, P.H., McCarthy, D.J., et al. Lanicemine: A low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol Psychiatry 19 (2014), 978–985.
15. 15 Zarate, C.A. Jr, Singh, J.B., Quiroz, J.A., De Jesus, G., Denicoff, K.K., Luckenbaugh, D.A., et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry 163 (2006), 153–155.
16. 16 Preskorn, S.H., Baker, B., Kolluri, S., Menniti, F.S., Krams, M., Landen, J.W., An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol 28 (2008), 631–637.
17. 17 Sanacora, G., What are we learning from early-phase clinical trials with glutamate targeting medications for the treatment of major depressive disorder. JAMA Psychiatry 73 (2016), 651–652.
18. 18 Newport, D.J., Carpenter, L.L., McDonald, W.M., Potash, J.B., Tohen, M., Nemeroff, C.B., et al. Ketamine and other NMDA antagonists: Early clinical trials and possible mechanisms in depression. Am J Psychiatry 172 (2015), 950–966.
19. 19 Gant, T.G., Using deuterium in drug discovery: Leaving the label in the drug. J Med Chem 57 (2014), 3595–3611.
20. 20 Autry, A.E., Adachi, M., Nosyreva, E., Na, E.S., Los, M.F., Cheng, P.F., et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475 (2011), 91–95.
21. 21 Li, N., Lee, B., Liu, R.J., Banasr, M., Dwyer, J.M., Iwata, M., et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329 (2010), 959–964.
22. 22 Maeng, S., Zarate, C.A. Jr, Du, J., Schloesser, R.J., McCammon, J., Chen, G., et al. Cellular mechanisms underlying the antidepressant effects of ketamine: Role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 63 (2008), 349–352.
23. 23 Thompson, S.M., Kallarackal, A.J., Kvarta, M.D., Van Dyke, A.M., LeGates, T.A., Cai, X., An excitatory synapse hypothesis of depression. Trends Neurosci 38 (2015), 279–294.